Overview

* Erasca ( ERAS ) reports Q3 net loss of $30.6 mln, similar to last year

* R&D expenses decreased to $22.5 mln from $27.6 mln year-over-year

* Company's cash position of $362 mln expected to fund operations into H2 2028

Outlook

* Company expects initial Phase 1 data for ERAS-0015 and ERAS-4001 in 2026

* Erasca's cash reserves expected to fund operations into H2 2028

Result Drivers

* PATENT ISSUANCE - U.S. patent issued for pan-RAS molecular glue ERAS-0015, strengthening intellectual property portfolio

* LEADERSHIP PROMOTION - Robert Shoemaker, Ph.D., promoted to chief scientific officer, reinforcing scientific leadership

* R&D expenses were $22.5 million for the quarter ended September 30, 2025, compared to $27.6 million for the quarter ended September 30, 2024

.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$30.61

Income mln

Q3 Basic -$0.11

EPS

Q3 $34.55

Operatin mln

g

Expenses

Q3 -$34.55

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Erasca Inc ( ERAS ) is $4.00, about 41% above its November 11 closing price of $2.36

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)